ESR1 and breast carcinoma: Bcl-2 and Bcl-xL are further elevated upon anti-estrogen treatment13–16, suggesting that ERα+ breast cancers may use anti-apoptotic Bcl-2 family members to drive cell survival and treatment resistance17, 18.